Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 7/20 | 0.33 |
| ▸ | CDK8 | P49336 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102467 | 0.94 | PDK2 (0.35) | CYP17A1CYP19A1CYP11B1CYP11B2AKR1C3 | |
| SCHEMBL1102676 | 0.92 | CYP11B1 (0.41) | CYP17A1CYP19A1CYP11B1CYP11B2TDO2 | |
| SCHEMBL1102592 | 0.91 | PDK2 (0.35) | AKR1C3AKR1C2KDRPDK2DGAT2 | |
| SCHEMBL1102782 | 0.91 | CYP11B2 (0.43) | CYP17A1CYP19A1CYP11B1CYP11B2TDO2 | |
| SCHEMBL1102594 | 0.91 | KDR (0.39) | CYP11B1CYP11B2AKR1C3AKR1C2KDR | |
| SCHEMBL1102725 | 0.89 | CYP11B1 (0.39) | CYP17A1CYP19A1CYP11B1CYP11B2TDO2 | |
| SCHEMBL1102647 | 0.89 | CYP11B1 (0.42) | CYP17A1CYP19A1CYP11B1CYP11B2TDO2 | |
| SCHEMBL1102465 | 0.88 | DGAT2 (0.36) | CYP17A1AKR1C3AKR1C2KDRPDK2 | |
| SCHEMBL1102570 | 0.87 | KDR (0.36) | AKR1C3AKR1C2KDRPDK2DGAT2 | |
| SCHEMBL10072718 | 0.87 | CYP17A1 (0.37) | CYP17A1CYP19A1CYP11B1CYP11B2TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | CYP17A1 2034/4885CYP19A1 1424/4885CYP11B1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.